amlodipine has been researched along with Anemia, Cooley's in 12 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of amlodipine in conjunction with standard chelation therapy may suggest a new strategy in preventing and treating iron overload in patients with thalassemia major, especially in organs where iron absorption depends on active uptake by calcium channels like the heart." | 9.17 | Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. ( Coelho, OR; Fernandes, JL; Fertrin, K; Loggetto, S; Piga, A; Saad, ST; Sampaio, EF; Verissimo, M, 2013) |
| "Despite the growing evidence supporting the role of amlodipine in reducing iron overload in thalassaemia patients, our meta-analysis did not find that evidence collectively significant." | 9.12 | Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies. ( Abbas, AS; Alhusseiny, A; Ebied, A; Elfaituri, MK; Fernandes, JL; Ghozy, S; Hassan, OG; Huy, NT; Morra, ME; Sherif, NA, 2021) |
| " Amlodipine, L-type calcium channel blocker with regular chelation therapy may reduce myocardial iron overload." | 5.51 | Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial. ( Aggarwal, P; Agrawal, V; Gupta, V; Kumar, I; Raj, V, 2022) |
| "Our meta-analysis found that amlodipine significantly increases cardiac T2* and decreases MIC, hence decreasing the incidence of cardiomyopathy-related iron overload in thalassemia patients." | 5.41 | Efficacy and safety of calcium channel blockers in preventing cardiac siderosis in thalassemia patients: An updated meta-analysis with trial sequential analysis. ( Abdelaziz, A; Abdelwahab, OA; Amer, BE; Badawy, MM; Diab, RA; Elsharkawy, A; Goudy, YM; Mouffokes, A; Soliman, Y, 2023) |
| "The addition of amlodipine to the standard chelation therapy in transfusion-dependent thalassemia major patients improves myocardial iron overload without increasing the adverse effects." | 5.30 | A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major. ( Ezzat, DA; Khaled, A; Rabee, H; Salem, HA; Seif, HM, 2019) |
| "The use of amlodipine in conjunction with standard chelation therapy may suggest a new strategy in preventing and treating iron overload in patients with thalassemia major, especially in organs where iron absorption depends on active uptake by calcium channels like the heart." | 5.17 | Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. ( Coelho, OR; Fernandes, JL; Fertrin, K; Loggetto, S; Piga, A; Saad, ST; Sampaio, EF; Verissimo, M, 2013) |
| "Despite the growing evidence supporting the role of amlodipine in reducing iron overload in thalassaemia patients, our meta-analysis did not find that evidence collectively significant." | 5.12 | Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies. ( Abbas, AS; Alhusseiny, A; Ebied, A; Elfaituri, MK; Fernandes, JL; Ghozy, S; Hassan, OG; Huy, NT; Morra, ME; Sherif, NA, 2021) |
| "Amlodipine treatment did not cause any serious adverse events." | 2.82 | A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major. ( Baldanzi, GR; Coelho, OR; Costa, FF; Fernandes, JL; Fertrin, KY; Fioravante, LA; Higa, T; Loggetto, SR; Mashima, DA; Piga, A; Saad, ST; Tan, DM; Veríssimo, MP, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 7 (58.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, V | 1 |
| Kumar, I | 1 |
| Raj, V | 1 |
| Aggarwal, P | 1 |
| Agrawal, V | 1 |
| Darvishi-Khezri, H | 2 |
| Khalilzadeh Arjmandi, H | 2 |
| Aliasgharian, A | 2 |
| Shaki, F | 1 |
| Zahedi, M | 1 |
| Kosaryan, M | 2 |
| Karami, H | 2 |
| Naeimayi Aali, R | 2 |
| Salehifar, E | 2 |
| Soliman, Y | 1 |
| Abdelaziz, A | 1 |
| Mouffokes, A | 1 |
| Amer, BE | 1 |
| Goudy, YM | 1 |
| Abdelwahab, OA | 1 |
| Badawy, MM | 1 |
| Diab, RA | 1 |
| Elsharkawy, A | 1 |
| Padhani, ZA | 1 |
| Gangwani, MK | 1 |
| Sadaf, A | 2 |
| Hasan, B | 2 |
| Colan, S | 2 |
| Alvi, N | 2 |
| Das, JK | 2 |
| Khaled, A | 1 |
| Salem, HA | 1 |
| Ezzat, DA | 1 |
| Seif, HM | 1 |
| Rabee, H | 1 |
| Alali, MA | 1 |
| Alanazi, KMA | 1 |
| Alsayil, SN | 1 |
| Omari, Z | 1 |
| Shaaban, A | 1 |
| Elfaituri, MK | 1 |
| Ghozy, S | 1 |
| Ebied, A | 1 |
| Morra, ME | 1 |
| Hassan, OG | 1 |
| Alhusseiny, A | 1 |
| Abbas, AS | 1 |
| Sherif, NA | 1 |
| Fernandes, JL | 3 |
| Huy, NT | 1 |
| Dabirian, M | 1 |
| Akbarzadeh, R | 1 |
| Nasirzadeh, A | 1 |
| Eghbali, A | 1 |
| Kazemi, H | 1 |
| Taherahmadi, H | 1 |
| Ghandi, Y | 1 |
| Rafiei, M | 1 |
| Bagheri, B | 1 |
| Sampaio, EF | 1 |
| Fertrin, K | 1 |
| Coelho, OR | 2 |
| Loggetto, S | 1 |
| Piga, A | 2 |
| Verissimo, M | 1 |
| Saad, ST | 2 |
| Loggetto, SR | 1 |
| Veríssimo, MP | 1 |
| Fertrin, KY | 1 |
| Baldanzi, GR | 1 |
| Fioravante, LA | 1 |
| Tan, DM | 1 |
| Higa, T | 1 |
| Mashima, DA | 1 |
| Costa, FF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major: a Randomized, Controlled Trial[NCT01395199] | Phase 3 | 62 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for amlodipine and Anemia, Cooley's
| Article | Year |
|---|---|
Efficacy and safety of calcium channel blockers in preventing cardiac siderosis in thalassemia patients: An updated meta-analysis with trial sequential analysis.
Topics: Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Humans; Iron; Iron Chelating Agents; Iron Ov | 2023 |
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Topics: Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Cardiomyopathies; Child; Edema; Ferritins; H | 2023 |
Calcium Channel Blockers in Conjunction with Standard Iron-Chelating Agents for β-Thalassemia Major: Systematic Literature Search.
Topics: Amlodipine; beta-Thalassemia; Biomarkers; Calcium Channel Blockers; Chelation Therapy; Drug Therapy, | 2020 |
Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies.
Topics: Amlodipine; beta-Thalassemia; Humans; Iron Chelating Agents; Iron Overload; Thalassemia | 2021 |
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Topics: Adolescent; Adult; Amlodipine; beta-Thalassemia; Blood Transfusion; Calcium Channel Blockers; Cardio | 2018 |
7 trials available for amlodipine and Anemia, Cooley's
| Article | Year |
|---|---|
Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial.
Topics: Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Chelation Therapy; Child; Ferritins; Humans; | 2022 |
Amlodipine: Can act as an antioxidant in patients with transfusion-dependent β-thalassemia? A double-blind, controlled, crossover trial.
Topics: Amlodipine; Antioxidants; beta-Thalassemia; Cross-Over Studies; Double-Blind Method; Glutathione; Hu | 2022 |
A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major.
Topics: Adolescent; Adult; Amlodipine; beta-Thalassemia; Calcium Channel Blockers; Child; Female; Humans; Ir | 2019 |
A double-blind, controlled, crossover trial of amlodipine on iron overload status in transfusion dependent β-thalassemia patients.
Topics: Amlodipine; beta-Thalassemia; Chelation Therapy; Cross-Over Studies; Humans; Iron Overload; Liver; M | 2021 |
A randomized, controlled study evaluating effects of amlodipine addition to chelators to reduce iron loading in patients with thalassemia major.
Topics: Adolescent; Adult; Amlodipine; beta-Thalassemia; Biomarkers; Cardiomyopathies; Chelation Therapy; Ch | 2017 |
Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial.
Topics: Adolescent; Adult; Amlodipine; Analysis of Variance; beta-Thalassemia; Calcium Channel Blockers; Che | 2013 |
A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major.
Topics: Administration, Oral; Adolescent; Adult; Amlodipine; beta-Thalassemia; Chelation Therapy; Child; Dou | 2016 |